2010
Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir
Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH. Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 511-514. PMID: 20672450, PMCID: PMC4841260, DOI: 10.1097/qai.0b013e3181d3cad3.Peer-Reviewed Original ResearchConceptsLPV/rBuprenorphine/naloxoneHIV-seronegative subjectsLopinavir/ritonavirOpioid withdrawalPharmacokinetic interactionsDaily lopinavir/ritonavirDaily LPV/rSteady-state pharmacokinetic evaluationBuprenorphine pharmacokineticsR administrationDosage modificationNaloxone concentrationsHistorical controlsPharmacodynamic responseAUC0-24hBaseline valuesPharmacokinetic evaluationNaloxonePharmacokinetic studySignificant differencesRitonavirNLXCmaxClearance
1998
Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262)
McCanceKatz E, Rainey P, Jatlow P, Friedland G. Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262). JAIDS Journal Of Acquired Immune Deficiency Syndromes 1998, 18: 435-443. PMID: 9715839, DOI: 10.1097/00042560-199808150-00004.Peer-Reviewed Original ResearchConceptsInjection drug usersMethadone treatmentChronic methadone treatmentMethadone-maintained patientsHeroin-addicted patientsMethadone effectsZDV doseZDV exposureZDV pharmacokineticsZDV treatmentZidovudine dispositionZidovudine therapyHIV diseaseMethadone levelsPharmacokinetic interactionsTherapeutic rangeRenal clearanceToxicity surveillanceSide effectsDrug usersDrug efficacyZDVClearanceAUCPatients